Stay updated on Amivantamab & Lazertinib in NSCLC Clinical Trial

Sign up to get notified when there's something new on the Amivantamab & Lazertinib in NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Amivantamab & Lazertinib in NSCLC Clinical Trial page

  1. Check
    5 days ago
    Change Detected
    Summary
    The clinical trial record for the amivantamab and lazertinib study is now available, with details on participation, treatment, study outcomes, locations, and related research information.
    Difference
    55%
    Check dated 2026-11-09T13:46:42.000Z thumbnail image
  2. Check
    12 days ago
    Change Detected
    Summary
    The footer revision label changed from v3.7.2 to v3.8.0. The study page continues to show a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-11-02T13:54:26.000Z thumbnail image
  3. Check
    19 days ago
    Change Detected
    Summary
    A sitewide NIH notice announces a transition in terminology from “Artificial Intelligence” to “Super Intelligence” and links to related updates and FAQs.
    Difference
    1%
    Check dated 2026-10-26T14:16:51.000Z thumbnail image
  4. Check
    26 days ago
    Change Detected
    Summary
    The site footer revision changed from v3.7.1 to v3.7.2 while the page continues to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-19T14:09:41.000Z thumbnail image
  5. Check
    33 days ago
    Change Detected
    Summary
    The footer revision identifier changes from v3.7.0 to v3.7.1, while the page continues to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-12T14:47:54.000Z thumbnail image
  6. Check
    53 days ago
    Change Detected
    Summary
    The page now displays a 403 Forbidden error, replacing the study record content. The visible elements indicate an access block preventing viewing trial details.
    Difference
    19%
    Check dated 2026-09-21T20:38:13.000Z thumbnail image

Stay in the know with updates to Amivantamab & Lazertinib in NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Amivantamab & Lazertinib in NSCLC Clinical Trial page.